Rachel Manci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rachel Manci has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Ashfaq A. Marghoob
Dermatology Service Memorial Sloan Kettering Cancer Center New York New York USA
2 shared publications - Adewole S. Adamson
Department of Internal Medicine, Dell Medical School, Austin, Texas; Division of Dermatology, Dell Medical School, University of Texas, Austin, Texas
1 shared publication Aditi Sahu
Department of Medicine, Dermatology Service Memorial Sloan Kettering Cancer Center New York New York USA
1 shared publication- Alexander Noor Shoushtari
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
1 shared publication - Charlotte Eielson Ariyan
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
1 shared publication - Chih-Shan Jason Chen
Department of Medicine, Dermatology Service Memorial Sloan Kettering Cancer Center New York New York USA
1 shared publication
Latest Publications
- 26 August 2026
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 58 (9) , 786-795
Reflectance Confocal Microscopy–Optical Coherence Tomography‐Guided Laser Ablation of Low‐Risk Basal Cell Carcinoma: A Long‐Term Prospective Follow‐Up Study
Objectives: The primary objective was to evaluate the long‐term recurrence rate following RCM–OCT‐guided laser ablation of basal cell carcinomas (BCCs). The secondary objective was to assess patient‐reported outcomes, including willingness to undergo the treatment again, scar acceptability, and adverse effects. Methods: A prospective cohort study evaluated 104 patients with 148 BCCs (2017–2021). Low risk BCC subtypes and with tumor depth of ≤ 300 µm were determined using RCM–OCT, and eligible lesions underwent same‐day Er:YAG laser ablation with immediate post‐treatment imaging to confirm clearance. Patients underwent clinical and RCM–OCT or RCM surveillance at 6 and 12 months and annually thereafter to assess recurrence. A patient‐reported questionnaire was conducted in 2023. Results: Fifty‐eight lesions (39.2%) in 39 patients met the criteria for laser ablation. Most lesions were located on the trunk (29/58, 50.0%), with median tumor depth and lesion size of 200 µm and 9.8 mm, respectively. Immediate post‐ablation RCM–OCT demonstrated imaging‐defined complete clearance after a single session in 53/58 lesions (91.4%). Residual tumors (5/58, 8.6%) were successfully treated during the same visit. Fifty‐four of 58 lesions (93.1%) had at least 6 months of follow‐up (median 32 months; min/max 8–70). One recurrence occurred at 53 months and was successfully retreated, corresponding to 1.04 recurrences per 100 person‐years of follow‐up. The patient‐reported questionnaire response rate was 79.5% (31/39). Overall, 96.8% (30/31) reported acceptable scar appearance, 83.9% (26/31) were likely to choose laser ablation again (Score 1–2 of 5), and 9.7% (3/31) reported mild, transient side effects. Conclusions: RCM–OCT‐guided Er:YAG laser ablation offers a “one‐stop” treatment approach for selected low‐risk BCCs, demonstrating low long‐term recurrence rates and high patient satisfaction.
- 26 August 2026
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 58 (9) , 786-795
Reflectance Confocal Microscopy–Optical Coherence Tomography‐Guided Laser Ablation of Low‐Risk Basal Cell Carcinoma: A Long‐Term Prospective Follow‐Up Study
Objectives: The primary objective was to evaluate the long‐term recurrence rate following RCM–OCT‐guided laser ablation of basal cell carcinomas (BCCs). The secondary objective was to assess patient‐reported outcomes, including willingness to undergo the treatment again, scar acceptability, and adverse effects. Methods: A prospective cohort study evaluated 104 patients with 148 BCCs (2017–2021). Low risk BCC subtypes and with tumor depth of ≤ 300 µm were determined using RCM–OCT, and eligible lesions underwent same‐day Er:YAG laser ablation with immediate post‐treatment imaging to confirm clearance. Patients underwent clinical and RCM–OCT or RCM surveillance at 6 and 12 months and annually thereafter to assess recurrence. A patient‐reported questionnaire was conducted in 2023. Results: Fifty‐eight lesions (39.2%) in 39 patients met the criteria for laser ablation. Most lesions were located on the trunk (29/58, 50.0%), with median tumor depth and lesion size of 200 µm and 9.8 mm, respectively. Immediate post‐ablation RCM–OCT demonstrated imaging‐defined complete clearance after a single session in 53/58 lesions (91.4%). Residual tumors (5/58, 8.6%) were successfully treated during the same visit. Fifty‐four of 58 lesions (93.1%) had at least 6 months of follow‐up (median 32 months; min/max 8–70). One recurrence occurred at 53 months and was successfully retreated, corresponding to 1.04 recurrences per 100 person‐years of follow‐up. The patient‐reported questionnaire response rate was 79.5% (31/39). Overall, 96.8% (30/31) reported acceptable scar appearance, 83.9% (26/31) were likely to choose laser ablation again (Score 1–2 of 5), and 9.7% (3/31) reported mild, transient side effects. Conclusions: RCM–OCT‐guided Er:YAG laser ablation offers a “one‐stop” treatment approach for selected low‐risk BCCs, demonstrating low long‐term recurrence rates and high patient satisfaction.
- Open Access
- 16 September 2025
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 8 (1) , e77714
Acral Persistent Papular Mucinosis in the United States: Case Series and Literature Review
Background: Acral persistent papular mucinosis (APPM) is a localized variant of lichen myxedematosus (LM) characterized by asymptomatic, flesh-colored papules primarily distributed on the hands and forearms. This chronic dermatosis, distinct from generalized mucinosis due to its lack of systemic involvement, remains underreported in medical literature. Objective: In this study, we present two cases of APPM to the limited pool of documented cases in the United States, highlighting its emerging recognition. Methods: This is a case series of two patients presenting with asymptomatic papular eruptions on the hands and wrists, consistent with the typical presentation of APPM. Diagnostic confirmation via biopsy revealed focal cutaneous mucinosis. Comprehensive laboratory evaluations, including serum and urine protein electrophoresis, showed no evidence of underlying gammopathy in either patient. Results: Treatment modalities for APPM are limited and often ineffective. Unlike other forms of LM, APPM features are confined to skin lesions, posing primarily as a cosmetic concern with a favorable prognosis. Accurate diagnosis of this localized LM is crucial to differentiate it from the more severe, generalized form, scleromyxedema, which can have organ involvement and may become fatal. Notably, while spontaneous resolution is reported in LM, including discrete papular mucinosis, APPM typically persists without resolution even after extended follow-up. Conclusions: These cases underscore the importance of recognizing APPM and advocating for broader awareness and exploration of its clinical variability, etiology, and management strategies. With increasing recognition, the understanding of APPM can be enhanced, paving the way for optimized management and improved outcomes for affected individuals.
- 16 September 2025
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 8 (1) , e77714
Open AccessAcral Persistent Papular Mucinosis in the United States: Case Series and Literature Review
Background: Acral persistent papular mucinosis (APPM) is a localized variant of lichen myxedematosus (LM) characterized by asymptomatic, flesh-colored papules primarily distributed on the hands and forearms. This chronic dermatosis, distinct from generalized mucinosis due to its lack of systemic involvement, remains underreported in medical literature. Objective: In this study, we present two cases of APPM to the limited pool of documented cases in the United States, highlighting its emerging recognition. Methods: This is a case series of two patients presenting with asymptomatic papular eruptions on the hands and wrists, consistent with the typical presentation of APPM. Diagnostic confirmation via biopsy revealed focal cutaneous mucinosis. Comprehensive laboratory evaluations, including serum and urine protein electrophoresis, showed no evidence of underlying gammopathy in either patient. Results: Treatment modalities for APPM are limited and often ineffective. Unlike other forms of LM, APPM features are confined to skin lesions, posing primarily as a cosmetic concern with a favorable prognosis. Accurate diagnosis of this localized LM is crucial to differentiate it from the more severe, generalized form, scleromyxedema, which can have organ involvement and may become fatal. Notably, while spontaneous resolution is reported in LM, including discrete papular mucinosis, APPM typically persists without resolution even after extended follow-up. Conclusions: These cases underscore the importance of recognizing APPM and advocating for broader awareness and exploration of its clinical variability, etiology, and management strategies. With increasing recognition, the understanding of APPM can be enhanced, paving the way for optimized management and improved outcomes for affected individuals.
- 1 September 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (3) , 430-432
Risk of nonacral cutaneous melanoma after the diagnosis of acral melanoma
- 1 September 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (3) , 430-432
Risk of nonacral cutaneous melanoma after the diagnosis of acral melanoma